SEQUOIA subgroup shows zanubrutinib sustains 64% PFS at 6 years in CLL patients ≥80, with low early discontinuations and ...
TRIDENT is a global, open-label, two-arm trial; secondary end points include progression-free survival, overall radiologic ...
Ziftomenib combinations show promising frontline AML results, expanding trials with chemo and targeted partners; phase 3 aims ...
Landau, MD, discussed promising results of CAR T-cell therapy in light chain amyloidosis and the challenge of developing ...
With multiple VEGFR-targeted therapies available after progression on immunotherapy-based regimens, oncologists continue to ...
Lupin Limited has received tentative approval from the FDA for its abbreviated new drug application (ANDA) for enzalutamide ...
KOMET-007 insights show ziftomenib’s manageable toxicity, low QTc risk, and easy oral dosing, supporting long-term AML ...
NCCN now recognizes personalized, tumor-informed ctDNA-MRD as a prognostic and predictive biomarker in MIBC, extending ...
Conversion from MRD negativity to positivity during maintenance is substantially lower with the quadruplet, and ...
Pettit, MD, discussed the potential of using treatment earlier in polycythemia vera to alter the disease course. During a ...
The standard of care established in the early 2000s is, in most respects, still the standard of care today—a fact that ...
Narjust Florez, MD, a thoracic medical oncologist at Dana-Farber Cancer Institute, discusses the clinical and structural gaps ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results